Vascepa
Payments companies reported to CMS as associated with Vascepa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vascepa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vascepa
These are the largest totals companies reported as associated with Vascepa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Paul Cohen | New York, NY | Cardiovascular Disease | $159,540.75 |
| Payal Kohli | Aurora, CO | Cardiovascular Disease | $111,137.53 |
| John Osborne | Grapevine, TX | Cardiovascular Disease | $104,264.60 |
| Matthew Budoff | Torrance, CA | Cardiovascular Disease | $37,259.96 |
| Michael Miller | Philadelphia, PA | Cardiovascular Disease | $28,746.52 |
| David Kovacich | Indianapolis, IN | Cardiovascular Disease | $21,935.28 |
| Odysseas Kostas | Greenwich, CT | Internal Medicine | $16,734.67 |
| Benjamin Hirsh | Manhasset, NY | Cardiovascular Disease | $15,742.94 |
| Gregory Pokrywka | Towson, MD | Internal Medicine | $13,589.02 |
| David Strobl | Lansing, MI | Cardiovascular Disease | $12,167.76 |
Prescribed Vascepa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.